Keitel W, Keitel R, Pap T
Rheumatologische Klinik, Fachkrankenhauses Vogelsang.
Z Gesamte Inn Med. 1993 Oct;48(10):480-3.
In a retrospective analysis a total of 167 patients with rheumatoid arthritis (RA) who had been treated with the basic therapy formulas of methotrexate (MTX) or sulfasalazine (SUL) were evaluated with respect to therapeutical result and side effects after a period of 12 months. There was no randomization as to either MTX (n = 87) or SUL therapy (n = 80), but deliberate use of therapy according to prior treatment and activity of the illness. Apart from a significantly higher number of inflammatory joint conditions in the MTX group there was no difference in the two patient groups at the beginning of the study. MTX treatment led clearly to a more conspicuous activity decrease of the illness (ESR, joint index) and a more favourable effect on the locomotor function. Furthermore, the sphygmomanometer readings (for grip strength determination), the dose reduction of the concomitant prednisolone medication as well as the doctor's opinion were in favour of MTX. The portion of patients who had to discontinue the therapy because of side effects (= 11%) and lack of effect (= 9%) was exactly identical in both groups of patients. Both substances have shown to be effective basic therapy formulas for rheumatoid arthritis, while methotrexate has a few advantages.
在一项回顾性分析中,对总共167例接受甲氨蝶呤(MTX)或柳氮磺胺吡啶(SUL)基础治疗方案的类风湿性关节炎(RA)患者进行了为期12个月的治疗效果和副作用评估。MTX治疗组(n = 87)和SUL治疗组(n = 80)并未进行随机分组,而是根据先前的治疗情况和疾病活动度进行有针对性的治疗。在研究开始时,除了MTX组的炎症性关节疾病数量明显较多外,两组患者在其他方面并无差异。MTX治疗明显使疾病活动度(血沉、关节指数)降低更为显著,对运动功能的改善效果也更佳。此外,血压测量值(用于测定握力)、同时服用的泼尼松龙药物剂量减少情况以及医生的评估结果均表明MTX更具优势。两组患者中因副作用而不得不停药的比例(= 11%)以及因治疗无效而停药的比例(= 9%)完全相同。两种药物均已证明是治疗类风湿性关节炎的有效基础治疗方案,但甲氨蝶呤具有一些优势。